AR and prostate cancer: Currently, several BET protein inhibitors (e.g., ZEN003694, OTX015/MK-8628, ABBV-075, INCB057643, GSK525762/I-BET762, GS-5829) are in phase I/II clinical trials, with some studies specifically assessing their efficacy in prostate cancer patients alone or in combination with AR-targeted therapies (112).